bioRxivCancer Biology
Macrophages foster adaptive anti-tumor immunity by ZEB1-dependent cytotoxic T cell chemoattraction
K. Fuchs, I. Armstark, R. van Roey, Y. Hajjaj, E. D`Avanzo, R. Liguori, F. Ferrazzi, J. Ackermann, L. Amon, M. Alfredo, M. Faas, J. Huebner, M. H. Hoffmann, G. Kroenke, C. Becker, D. Dudziak, F. Nimmerjahn, S. Brabletz, M. P. Stemmler, T. Brabletz, H. Schuhwerk
Abstract
Tumor-associated macrophages (TAMs) shape the tumor microenvironment (TME) and exert a decisive impact on anti-tumor immunity. Understanding TAM function is therefore critical to understand anti-tumor immune responses and to design immunotherapies. Here, we describe the transcription factor ZEB1, a well-known driver of epithelial-to-mesenchymal transition, as an intrinsic regulator of TAM function in adaptive anti-tumor immunity. By combining cell type-specific deletion of Zeb1 with syngeneic models of colorectal and pancreatic cancer, we discovered an unexpected function of ZEB1 in the TAM-mediated control of T cell trafficking. ZEB1 supports secretion of a subset of chemokines including CCL2 and CCL22 by promoting their transcription and translation as well as by safeguarding protein processing. ZEB1 thereby elevates cytotoxic T cell (CTL) recruitment in vitro and in vivo and fosters immunosurveillance during tumor as well as lung metastatic outgrowth. Our study spotlights ZEB1 as a crucial facilitator of adaptive anti-tumor immunity and uncovers a potential therapeutic window of opportunity for cytokine-guided enhancement of CTL infiltration into tumors and metastases.
- organism: mouse
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: cell-cell communication
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ZEB1-dependent modulation of fibroblast polarization governs inflammation and immune checkpoint blockade sensitivity in colorectal cancer
H. Schuhwerk, C. Menche, … M. P. Stemmler·bioRxiv·Mar 28, 2023
- Inhibition of the transcription factor PU.1 suppresses tumor growth in mice by promoting the recruitment of cytotoxic lymphocytes through the CXCL9-CXCR3 axis
Nichita Sleapnicov, Soon-Duck Ha, … Sung Ouk Kim·CancersPeer-reviewed·Aug 18, 2025
- CAR-MACROPHAGES ACTIVATE ANTI TUMOR T CELLS IN THE ABSENCE OF PHAGOCYTOSIS
Lea C. Feldmann, Amaury Vaysse, … Capucine L. Grandjean·bioRxiv·Aug 28, 2026
- High-motility pro-tumorigenic monocytes drive macrophage enrichment in the tumor microenvironment
Wenxuan Du, Bryan Zhou, … Denis Wirtz·bioRxiv·Jul 16, 2024
- Engineered CD47 protects T cells for enhanced antitumor immunity
S. A. Yamada-Hunter, J. Theruvath, … C. L. Mackall·bioRxiv·Jun 20, 2023
- ImmTACs overcome cytotoxic T cell suppression
Lan Huynh, Abdullah Aljohani, … Christoph Wülfing·Immunotherapy AdvancesPeer-reviewed·Dec 31, 2025